Asset profile
HLX43
Antibody–drug conjugate
Evidence outlook · registrational
Non-Small Cell Lung Cancer: registrational readout pending
Its supporting mid-stage evidence has not yet been graded on this platform. Registrational readout expected around 2030-01-15.
Also in development:HR+/HER2- Metastatic Breast Cancer · Phase 2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
126 competitors in this universe: 10 direct rivals (same mechanism and indication), 1 same-class, 115 same-indication; 120 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| HLX43: this drug | Phase 2/3 | Antibody–drug conjugate | PD-L1 | ||
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | ||
| Durvalumab | Approved | Monoclonal antibody | PD-L1 | ||
| Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs) | Approved | Monoclonal antibody | PD-L1 | ||
| Adebrelimab | Phase 3 | Monoclonal antibody | PD-L1 | ||
| CS1001 Monoclonal Antibody | Phase 3 | Monoclonal antibody | PD-L1 | ||
| Envafolimab | Phase 3 | Monoclonal antibody | PD-L1 | ||
| KL-A167 | Phase 3 | Monoclonal antibody | PD-L1 | ||
| PF-08046054 | Phase 3 | Antibody–drug conjugate | PD-L1 | ||
| 177Lu-RAD204 | Phase 1 | Radiopharmaceutical | PD-L1 | ||
| BPI-371153 | Phase 1 | Small molecule | PD-L1 | ||
| IBC-Ab002 | Phase 1 | Monoclonal antibody | PD-L1 | ||
| Abemaciclib (Verzenio) | Approved | Small molecule | CDK4 and CDK6 | ||
| Afatinib (Gilotrif) | Approved | Small molecule | EGFR/HER1, HER2, HER4 | ||
| Alectinib (Alecensa) | Approved | Small molecule | ALK | ||
| Alpelisib (BYL719) | Approved | Small molecule | PI3K-alpha |
…and 111 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(15 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (7)
October 2026 (3)
What to watch
What to watch
What to watch
November 2026 (1)
What to watch
December 2026 (3)
What to watch
What to watch
What to watch
2027 (5)
May 2027 (1)
What to watch
June 2027 (1)
What to watch
July 2027 (1)
What to watch
August 2027 (1)
What to watch
December 2027 (1)
What to watch
2028 (2)
2030 (1)
January 2030 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.